Nadia Khan, MD
Nadia Khan MD, is the Director of the CLL Division at the Center for Blood Disorders and Cellular Therapy at Swedish Cancer Insitute in Seattle. She is committed to the implementation and development of clinical trials utilizing novel targeted agents in the management of CLL and lymphomas. Dr. Khan served on the NCCN committee panels for lymphoma and CLL, prior to her appointment at Swedish.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AdaptiveTopic:Cell Free DNADate added:05/05/2023Date updated:05/05/2023Relationship end date:12/22/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BeigeneTopic:CLLDate added:05/05/2023Date updated:05/05/2023Relationship end date:11/22/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PCYCDate added:05/05/2023Date updated:05/05/2023Relationship end date:05/08/2024